



Jounce Therapeutics (USA): Constituent Deletion

Changes in Russell Pure Style Index Series

01 May 2023

Subject to the completion of the tender offer for Jounce Therapeutics (USA, constituent) by Concentra Biosciences LLC, please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
Russell 2000 Pure Value	04 May 2023

*The removal is being expedited ahead of the offer expiration in line with section 4.10 of the Corporate Actions and Events Guide when Contingent Value Rights (CVRs) are included in the terms.

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia	+1800 653 680
Hong Kong	+852 2164 3333
Japan	+81 3 6441 1430
London	+44 (0) 20 7866 1810
New York	+1866 551 0617

Alternatively please visit our website at www.ftserussell.com

[Terms of Use](#) | Copyright © 2023 FTSE Russell